HOME >> MEDICINE >> NEWS
SNM and ACNP CMS PET reimbursement statement

CMS new reimbursement rate for FDG PET of $1375.00 has both good and disappointing news for those interested in bringing Positron Emission Tomography (PET) to the broadest number of patients, according to the Society of Nuclear Medicine (SNM) and the American College of Nuclear Physicians (ACNP).

SNM and ACNP believe that this lower rate (down from the previous $2,331.18) may have a negative impact on the expansion of PET services into communities where it does not currently exist, since it will be more difficult for hospitals and other facilities to recoup the significant costs associated with the installation and operation of PET centers. This is unfortunate, since PET is increasingly used in clinical medicine, and is a vital diagnostic and treatment planning tool for many cancers, neurological and cardiac conditions.

On the positive side, SNM and ACNP are pleased at CMSs responsiveness to the concerns expressed when proposed reduced reimbursement amounts were first posted in August. This was particularly significant as it relates to the cost of the 18-flurodeoxyglocose (FDG) injected as part of the PET scan process. CMS originally proposed an FDG PET reimbursement of $841.50, when the published average wholesale price (AWP) for FDG is $750. Facilities would lose money with each scan.

This process demonstrated that the medical profession and the government can work together, stated Alan Maurer, M.D., President of the SNM. We were able to show how there were errors in the data on which CMS had originally based its proposed reimbursement, and the agency responded by developing a more reasonable, though still disappointing, reimbursement amount.

Because CMS relies on data to make its reimbursement decisions, this effort also demonstrates how important it is for those of us in the PET field to be particularly precise when we code and submit claims to the agency. We look forward to working with CMS in the future on this, and to e
'"/>

Contact: William Uffelman
wuffelman@snm.org
703-708-9000
Society of Nuclear Medicine
30-Nov-2001


Page: 1 2

Related medicine news :

1. Study finds Medicare overbilling may be caused by governments faulty reimbursement
2. NHLBI statement on oral contraceptive study
3. NIH panel issues State-of-the-Science statement on end-of-life care
4. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
5. American Heart Association consensus statement
6. NIA statement on IOM testosterone report
7. American Psychiatric Association issues statement on compulsive shopping
8. New statement proposes ways to stop deadly drug errors among heart, stroke patients
9. Aventis Pasteur statement on HVTN 501 decision

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2016)... ... May 23, 2016 , ... ... and sexual objectification, according to Georgia State University researchers. , In ... in the fifth, sixth and seventh grades shared their experiences with strained ...
(Date:5/23/2016)... ... May 23, 2016 , ... Cosmetic Town, an ... about cosmetic procedures, began updating their library of over 300 encyclopedic medical articles. ... articles in order to feature the latest breakthroughs in plastic surgery procedures since ...
(Date:5/23/2016)... WASHINGTON, D.C. (PRWEB) , ... May 23, 2016 , ... ... Phyllis Greenberger, MSW, has decided to move on from that role. , “No one ... years as did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer ...
(Date:5/23/2016)... ... 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch and Rajat ... the end of 2016. , “We created IPOB to change the dialogue around ... back on what we have achieved, we’re gratified by the response of wine producers, ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a ... is proud to announce the launch of its new extended care program, Fifth Circle. ... treatment at Four Circles or another primary treatment program, Fifth Circle is designed to ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... SAN FRANCISCO, Calif. , May 19, 2016 /PRNewswire/ ... a biopharmaceutical company developing novel therapeutics for the treatment ... announced that new GBT440 data will be presented in ... 21 st Congress in Copenhagen ... ongoing Phase 1/2 GBT440-001 study in sickle cell disease ...
(Date:5/19/2016)... 2016 BioLineRx Ltd. (NASDAQ/TASE: BLRX) ... treatment of multiple cancer and hematological indications, will be ... abstract titled " Clinical response in relapsed/refractory AML patients ... BL-8040, a potent CXCR4 antagonist; results of a Phase ... at the European Hematology Association 21st Congress, to be ...
(Date:5/19/2016)... CAMBRIDGE, Massachusetts , May 19, 2016 ... pharmaceuticals and diagnostics based on the gut microbiome, is pleased ... Cambridge, MA to support its operations ... office is located at Kendall Square, the heart of ... global hub for transforming scientific insights into new drugs. The ...
Breaking Medicine Technology:
Cached News: